A "significant breakthrough" in HIV prevention could be on the horizon, according to the World Health Organization. Results of an interim analysis from a Phase 3 clinical trial sponsored by Gilead Sciences, Inc., showed that lenacapavir, a twice-yearly injectable drug, is a highly promising tool for thwarting new HIV infections. Dr. Onyema Ogbuagu is the study's principal investigator.
More from Yale School of Medicine
Published: Sunday, November 3, 2024
